A new biotech has sprung out of stealth with a bold vision to develop the “greatest therapeutic of all time”—a drug that can ...

North Immunology has decided its path to taking its atopic dermatitis (AD) drug into the clinic involves going public via a ...

Novo’s race to rejuvenate its cardiometabolic portfolio has seen the rebranded Danish pharma pen a $1.4 biobucks pact with ...

A rare inherited germline mutation was found to increase risk for lung cancer by 25 times, while smoking only increased risk by 4 times.

Roche is paying Dualitas Therapeutics $36.5 million upfront to screen over 300,000 novel bispecific combinations in search of new treatments for immunology and inflammation diseas ...

A phase 2b study of Longeveron’s stem cell therapy in a pediatric heart disease has missed its primary endpoint, prompting ...

Novartis has extended its losing streak, stopping an amyotrophic lateral sclerosis (ALS) program after flunking a phase 2 ...

SK Biopharmaceuticals has added a second preclinical Parkinson’s disease therapy to its pipeline courtesy of a $314.8 million biobucks deal with a fellow South Korean drug developer. The deal centers ...

After teasing a new initiative to speed up early-stage clinical trials over the summer, the FDA today opened a pilot program ...

Connect Biopharma’s hopes of dethroning Dupixent took a knock as its IL-4/IL-13 blocker missed the primary endpoint of a ...

To keep the resources flowing to this new strategy, Sionna is reducing its headcount by around 46%, including the departure ...

Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead Sciences’ CEO ...